3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
20
pembrolizumab
19
Nivolumab
10
fludarabine
7
Radiosurgery
7
Specimen Handling
6
Ipilimumab
6
Injections
5
Celecoxib
5
poly ICLC
4
Radiation
4
Paclitaxel
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Docetaxel
4
Cryosurgery
4
durvalumab
3
cemiplimab
3
Filgrastim
3
Etoposide
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
bempegaldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled